[go: up one dir, main page]

PE20161218A1 - (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 - Google Patents

(2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1

Info

Publication number
PE20161218A1
PE20161218A1 PE2016001236A PE2016001236A PE20161218A1 PE 20161218 A1 PE20161218 A1 PE 20161218A1 PE 2016001236 A PE2016001236 A PE 2016001236A PE 2016001236 A PE2016001236 A PE 2016001236A PE 20161218 A1 PE20161218 A1 PE 20161218A1
Authority
PE
Peru
Prior art keywords
oxazepan
carboxamides
phenylethyl
cyano
cyane
Prior art date
Application number
PE2016001236A
Other languages
English (en)
Inventor
Carl-Johan Aurell
Stephen Connolly
Kevin James Doyle
Graham Peter Jones
Hans Roland Lonn
David Wyn Watson
Nicholas John Palmer
Karlsson Staffan Po
John Fritiof Ponten
Steven Swallow
De Poel Amanda Jane Van
Jaqueline Anne Macritchie
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20161218(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20161218A1 publication Critical patent/PE20161218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se refiere a un compuesto derivado de (2S)-N-[(1S)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas de formula I o sales farmaceuticamente aceptables, donde: R1 es (a); R2 es hidrogeno, F, Cl, Br, entre otros; R3 es hidrogeno, F, Cl, CN, entre otros; o R1 es (b), (c), entre otros, donde: X es O, S o CF2; Y es O o S; R6 es alquilo C1-C3 opcionalmente sustituido por 1, 2 o 3 F, OH, entre otros; R7 es F, Cl o CH3. Son compuestos preferidos: (2S)-N-[(1S)-1-Ciano-2-(4'-cianobifenil-4-il)etil]-1,4-oxazepan-2-carboxamida; (2S)-N-{(1S)-1-Ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepan-2-carboxamida; entre otros. Tambien se refiere a un metodo de tratamiento y a una composicion farmaceutica. Dichos compuestos inhiben la actividad de la dipeptidilpeptidasa (DPP1), siendo utiles en el tratamiento de enfermedades respiratorias tales como asma, enfermedad pulmonar obstructiva cronica (COPD), entre otros
PE2016001236A 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 PE20161218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24

Publications (1)

Publication Number Publication Date
PE20161218A1 true PE20161218A1 (es) 2016-11-27

Family

ID=52432834

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001236A PE20161218A1 (es) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1

Country Status (38)

Country Link
US (18) US9522894B2 (es)
EP (4) EP4548972A3 (es)
JP (7) JP6469711B2 (es)
KR (1) KR102417684B1 (es)
CN (2) CN105980367B (es)
AP (1) AP2016009322A0 (es)
AR (1) AR099177A1 (es)
AU (4) AU2015208932C1 (es)
BR (1) BR112016016224B1 (es)
CA (1) CA2935625C (es)
CL (1) CL2016001889A1 (es)
CR (1) CR20160327A (es)
CY (2) CY1120049T1 (es)
DK (3) DK3744714T3 (es)
DO (1) DOP2016000175A (es)
EA (1) EA032794B1 (es)
ES (3) ES2658516T3 (es)
FI (1) FI3744714T3 (es)
HR (3) HRP20250302T1 (es)
HU (3) HUE052421T2 (es)
IL (3) IL246614B (es)
LT (3) LT3323814T (es)
MX (1) MX368840B (es)
MY (1) MY194850A (es)
NO (1) NO2699580T3 (es)
NZ (2) NZ722063A (es)
PE (1) PE20161218A1 (es)
PH (1) PH12016501439B1 (es)
PL (3) PL3323814T3 (es)
PT (3) PT3744714T (es)
RS (3) RS66709B1 (es)
SG (2) SG10201701056QA (es)
SI (3) SI3323814T1 (es)
SM (3) SMT201800058T1 (es)
TW (1) TWI690517B (es)
UY (1) UY35963A (es)
WO (1) WO2015110826A1 (es)
ZA (2) ZA201605856B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (es) 2014-01-24 2018-02-24
KR20190035781A (ko) * 2016-07-29 2019-04-03 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
ES3011730T3 (en) 2018-03-01 2025-04-08 Astrazeneca Ab Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
KR20210032431A (ko) * 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CA3106270A1 (en) * 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
EP4048280A4 (en) * 2019-10-23 2023-11-15 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating chronic obstructive pulmonary diseases (copd)
CN116157687A (zh) * 2020-07-20 2023-05-23 英斯梅德股份有限公司 用于提取嗜中性粒细胞丝氨酸蛋白酶以及治疗二肽基肽酶1介导的病症的方法
PL4129989T3 (pl) * 2020-08-26 2025-02-24 Haisco Pharmaceuticals Pte. Ltd. Pochodna nitrilu działająca jako inhibitor dipeptydylopeptydazy 1 i jej zastosowanie
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022117059A1 (zh) 2020-12-04 2022-06-09 瑞石生物医药有限公司 组织蛋白酶c小分子抑制剂及其医药用途
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
WO2022166721A1 (zh) * 2021-02-05 2022-08-11 南京明德新药研发有限公司 含1，4-氧杂氮杂环庚烷的并环类衍生物
KR20240004691A (ko) * 2021-04-29 2024-01-11 인스메드 인코포레이티드 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드
CA3236069A1 (en) * 2021-10-29 2023-05-04 Ariel Teper Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CN116332937A (zh) * 2021-12-23 2023-06-27 杭州邦顺制药有限公司 二肽基肽酶ⅰ抑制剂及其用途
JP2025504817A (ja) * 2022-01-11 2025-02-19 上海壹典医▲薬▼科技▲開▼▲発▼有限公司 ペプチジルニトリル化合物及びその使用
KR20240148350A (ko) * 2022-02-16 2024-10-11 인스메드 인코포레이티드 화농성한선염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드
CN118742547A (zh) 2022-02-22 2024-10-01 西藏海思科制药有限公司 一种含氮杂环化合物的制备方法
MX2024010266A (es) 2022-02-22 2024-08-28 Haisco Pharmaceuticals Pte Ltd Polimorfo inhibidor de la dipeptidil peptidasa 1, método de preparación y uso del mismo.
CA3243683A1 (en) 2022-02-22 2025-01-22 Haisco Pharmaceuticals Pte. Ltd. SALT AND CRYSTALLINE FORM OF DIPEPTIDYLPEPTIDASE INHIBITOR COMPOUND
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
CA3255979A1 (en) 2022-06-07 2025-03-18 Reistone Biopharma Company Limited PHARMACEUTICALLY ACCEPTABLE SALT OF A BENZO[C]CHROMANE COMPOUND, POLYMORPHIC FORM AND USE OF A PHARMACEUTICALLY ACCEPTABLE SALT
US20250353839A1 (en) * 2022-06-07 2025-11-20 Reistone Biopharma Company Limited Polymorph of benzo[c]chroman compound, preparation method therefor and use thereof
CN119317620A (zh) 2022-06-13 2025-01-14 亚力维克希斯股份有限公司 氮杂环烷基羰基环状胺化合物
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024081889A1 (en) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
CN119948034A (zh) * 2022-10-26 2025-05-06 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
AU2024206233A1 (en) 2023-01-06 2025-08-21 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
EP4665717A2 (en) * 2023-02-15 2025-12-24 Insmed Incorporated Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors
TW202442238A (zh) 2023-03-23 2024-11-01 大陸商西藏海思科製藥有限公司 二肽基肽酶小分子抑制劑的藥物组合物
WO2025059526A1 (en) * 2023-09-15 2025-03-20 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
USD1099133S1 (en) * 2024-02-01 2025-10-21 Apple Inc. Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
DK1317555T3 (da) 2000-09-08 2008-03-25 Prozymex As Dipeptidylpeptidase i krystalstruktur og anvendelser heraf
DE60135764D1 (de) * 2000-10-06 2008-10-23 Mitsubishi Tanabe Pharma Corp Stickstoffhaltige, fünfgliedrige ringverbindungen
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
BR0214642A (pt) 2001-12-04 2004-11-03 Hoffmann La Roche Compostos, métodos para a preparação de um composto, composições farmacêuticas que compreendem o mesmo e método para o tratamento e/ou prevenção de enfermidades que estão associadas com protéases de cisteìna e utilização desses compostos
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
EP1975153A3 (en) 2003-05-30 2010-03-31 Prozymex A/S Protease inhibitors
JP2006527704A (ja) * 2003-06-18 2006-12-07 プロザイメックス・アクティーゼルスカブ プロテアーゼ阻害剤
SG152226A1 (en) 2004-04-07 2009-05-29 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP2017620A3 (en) 2004-04-28 2009-04-22 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
JP5438898B2 (ja) 2004-06-29 2014-03-12 タケダ ファーマ アクティーゼルスカブ 水不溶性薬剤の速放性医薬組成物の製造と、本発明の方法で得られた医薬組成物
EP1778224B1 (en) 2004-07-19 2014-03-26 The Johns-Hopkins University Flt3 inhibitors for immune suppression
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
EP1896461A2 (en) 2005-06-30 2008-03-12 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
CA2680312A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
AU2008305591A1 (en) 2007-09-25 2009-04-02 Nektar Therapeutics Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
JP2011506421A (ja) * 2007-12-12 2011-03-03 アストラゼネカ・アクチエボラーグ ペプチジルニトリル類およびジペプチジルペプチダーゼｉ阻害剤としてのその使用
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
US9040508B2 (en) 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
DK2413913T3 (da) 2009-04-01 2022-06-13 Bial Portela & Ca Sa Farmaceutiske formuleringer omfattende nitrocatecholderivater og fremgangsmåder til fremstilling deraf
EA201190235A1 (ru) * 2009-05-07 2012-05-30 Астразенека Аб Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
EP4005559B1 (en) 2010-04-07 2025-02-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
EP2672821B9 (en) 2011-02-11 2016-11-23 GlaxoSmithKline Intellectual Property Development Limited Cathepsin c inhibitors
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
AU2013224421B2 (en) 2012-02-21 2017-03-02 Merck Patent Gmbh 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
ES2644965T3 (es) 2012-04-17 2017-12-01 Astellas Pharma Inc. Compuesto heterocíclico aromático bicíclico nitrogenado
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
JP6441831B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．２］オクタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
JP6437929B2 (ja) 2013-03-14 2018-12-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
US8871783B2 (en) 2013-03-14 2014-10-28 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin C
TW201522307A (zh) 2013-03-14 2015-06-16 百靈佳殷格翰國際股份有限公司 經取代２－氮雜－雙環［２．２．１］庚烷－３－羧酸（苄基－氰基－甲基）－醯胺組織蛋白酶ｃ抑制劑
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
WO2015027039A1 (en) 2013-08-22 2015-02-26 Emory University Devices and methods related to airway inflammation
CA2923484C (en) 2013-09-09 2022-09-06 Prozymex A/S Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (es) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
IL305337A (en) 2014-04-10 2023-10-01 Novartis Ag A therapeutic regimen containing an immediate release dose of an S1P modulator
PT3142643T (pt) 2014-05-15 2019-10-28 Insmed Inc Métodos para o tratamento de infeções mico bacterianas pulmonares não tuberculares
EP3149192B1 (en) 2014-05-30 2019-01-02 Versitech Limited Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
EP3174879B1 (en) 2014-08-01 2018-07-18 Boehringer Ingelheim International GmbH Substituted oxetanes and their use as inhibitors of cathepsin c
CA2960916C (en) 2014-09-12 2023-03-07 Boehringer Ingelheim International Gmbh Spirocyclic inhibitors of cathepsin c
US10071974B2 (en) 2014-11-14 2018-09-11 Boehringer Ingelheim International Gmbh Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists
JP6783426B2 (ja) 2015-03-05 2020-11-11 ニュープロザイム・セラピューティクス・アンパルトセルスカブＮｅｕｐｒｏｚｙｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡｐＳ ジペプチジルペプチダーゼｉ阻害剤としてのペプチジルニトリル化合物
KR20190035781A (ko) 2016-07-29 2019-04-03 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
ES3011730T3 (en) 2018-03-01 2025-04-08 Astrazeneca Ab Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CA3106270A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
EP3955889A1 (en) 2019-04-17 2022-02-23 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
KR20220026538A (ko) 2019-06-05 2022-03-04 에모리 유니버시티 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
KR20240004691A (ko) 2021-04-29 2024-01-11 인스메드 인코포레이티드 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드
CA3236069A1 (en) 2021-10-29 2023-05-04 Ariel Teper Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
KR20240148350A (ko) 2022-02-16 2024-10-11 인스메드 인코포레이티드 화농성한선염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드

Also Published As

Publication number Publication date
AU2017200338B2 (en) 2018-03-01
JP2023156479A (ja) 2023-10-24
JP2022096662A (ja) 2022-06-29
HK1225730B (en) 2017-09-15
LT3744714T (lt) 2025-04-10
US11673871B2 (en) 2023-06-13
JP2019070029A (ja) 2019-05-09
SI3097086T1 (en) 2018-04-30
US20230115170A1 (en) 2023-04-13
CR20160327A (es) 2016-10-20
ES2658516T3 (es) 2018-03-12
US20230062646A1 (en) 2023-03-02
ZA201800431B (en) 2019-09-25
UY35963A (es) 2015-07-31
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
NO2699580T3 (es) 2018-02-24
EP4548972A2 (en) 2025-05-07
DOP2016000175A (es) 2016-08-15
PT3744714T (pt) 2025-04-07
HUE070606T2 (hu) 2025-06-28
TWI690517B (zh) 2020-04-11
RS56919B1 (sr) 2018-05-31
US11117874B2 (en) 2021-09-14
BR112016016224A2 (es) 2017-08-08
US11655221B2 (en) 2023-05-23
US10287258B2 (en) 2019-05-14
US20230033573A1 (en) 2023-02-02
IL265611A (en) 2019-05-30
CN110483492B (zh) 2023-07-21
EP3323814B1 (en) 2020-05-13
AU2019202675B2 (en) 2020-05-28
US11814359B2 (en) 2023-11-14
NZ722063A (en) 2017-09-29
US11667615B2 (en) 2023-06-06
JP2017503832A (ja) 2017-02-02
US20210238152A1 (en) 2021-08-05
KR20160111470A (ko) 2016-09-26
PH12016501439A1 (en) 2017-02-06
EA032794B1 (ru) 2019-07-31
US20240336582A1 (en) 2024-10-10
US20180251436A1 (en) 2018-09-06
ZA201605856B (en) 2020-02-26
CN105980367B (zh) 2019-08-23
US20240132455A1 (en) 2024-04-25
US11655223B2 (en) 2023-05-23
HRP20180116T1 (hr) 2018-03-23
US11673872B2 (en) 2023-06-13
AP2016009322A0 (en) 2016-07-31
SMT201800058T1 (it) 2018-03-08
HUE052421T2 (hu) 2021-04-28
US20230278969A1 (en) 2023-09-07
CA2935625A1 (en) 2015-07-30
HRP20201147T1 (hr) 2020-12-11
US20150210655A1 (en) 2015-07-30
PH12016501439B1 (en) 2017-02-06
US20200017455A1 (en) 2020-01-16
JP7336563B2 (ja) 2023-08-31
ES2808060T3 (es) 2021-02-25
FI3744714T3 (fi) 2025-04-01
JP7628587B2 (ja) 2025-02-10
AU2015208932A8 (en) 2017-03-09
LT3323814T (lt) 2020-10-26
AU2017200338A1 (en) 2017-02-02
US20230025351A1 (en) 2023-01-26
AU2015208932C1 (en) 2017-05-25
PL3744714T3 (pl) 2025-09-08
EP3744714A1 (en) 2020-12-02
SMT202000433T1 (it) 2020-09-10
MX368840B (es) 2019-10-18
CN105980367A (zh) 2016-09-28
CA2935625C (en) 2022-10-18
HK1255870A1 (en) 2019-08-30
DK3097086T3 (en) 2018-02-05
PL3323814T3 (pl) 2020-10-19
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
WO2015110826A1 (en) 2015-07-30
US9815805B2 (en) 2017-11-14
JP6469711B2 (ja) 2019-02-13
US20230028726A1 (en) 2023-01-26
US11655222B2 (en) 2023-05-23
LT3097086T (lt) 2018-02-26
US20200247765A1 (en) 2020-08-06
CL2016001889A1 (es) 2016-12-09
RS66709B1 (sr) 2025-05-30
AU2019202675A1 (en) 2019-05-16
JP7714823B2 (ja) 2025-07-29
US12054465B2 (en) 2024-08-06
HRP20250302T1 (hr) 2025-04-25
ES3018635T3 (es) 2025-05-16
US11655224B2 (en) 2023-05-23
MY194850A (en) 2022-12-19
AU2015208932B8 (en) 2017-03-09
EA201691375A1 (ru) 2017-01-30
JP2021046423A (ja) 2021-03-25
EP3097086A1 (en) 2016-11-30
DK3323814T3 (da) 2020-08-03
CY1123391T1 (el) 2021-12-31
SG10201701056QA (en) 2017-03-30
NZ734768A (en) 2022-09-30
PT3323814T (pt) 2020-08-05
US20170057938A1 (en) 2017-03-02
US9522894B2 (en) 2016-12-20
CY1120049T1 (el) 2018-12-12
US10669245B2 (en) 2020-06-02
AU2018202956B2 (en) 2019-05-09
TW201612167A (en) 2016-04-01
IL252836A0 (en) 2017-08-31
US20230116721A1 (en) 2023-04-13
EP3097086B1 (en) 2017-12-13
US20230085620A1 (en) 2023-03-23
CN110483492A (zh) 2019-11-22
MX2016009349A (es) 2016-10-13
AR099177A1 (es) 2016-07-06
SMT202500137T1 (it) 2025-05-12
DK3744714T3 (da) 2025-04-07
US20230069044A1 (en) 2023-03-02
SG11201606052TA (en) 2016-08-30
KR102417684B1 (ko) 2022-07-05
RS60639B1 (sr) 2020-09-30
JP2025157389A (ja) 2025-10-15
US11680049B2 (en) 2023-06-20
PL3097086T3 (pl) 2018-04-30
SI3744714T1 (sl) 2025-05-30
US20230250071A1 (en) 2023-08-10
JP7157791B2 (ja) 2022-10-20
AU2015208932B2 (en) 2017-02-16
EP3323814A1 (en) 2018-05-23
SI3323814T1 (sl) 2020-10-30
BR112016016224B1 (pt) 2023-02-23
AU2015208932A1 (en) 2016-07-28
EP4548972A3 (en) 2025-06-25
JP6804570B2 (ja) 2020-12-23
AU2018202956A1 (en) 2018-05-17
JP2025072423A (ja) 2025-05-09
EP3744714B1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
PE20161218A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
DOP2019000010A (es) Compuesto (r)-n-(5-cloro-1-(3,3-difluoro-1-(oxetan-3-il)piperidin-4-il)-1h-pirazol-4-il)-4-etoxi-7h-pirrolo[2,3-d]pirimidin-2-amina o sal farmacéuticamente aceptable del mismo
UY35243A (es) Inhibidores de fosfatidilinositol 3-cinasa
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
TN2014000033A1 (fr) Indazoles
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PE20142305A1 (es) Compuestos de n-ariltriazol como antagonistas de lpar
JOP20130256B1 (ar) مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
MX394356B (es) Métodos y composiciones para tratar hiperhidrosis.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201790088A1 (ru) Ингибиторы syk
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
PE20160194A1 (es) Composiciones y metodos para tratar anemia
PE20151666A1 (es) Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
PE20161432A1 (es) Compuestos y composiciones para inducir condrogenesis
EA201391337A1 (ru) Ингибиторы hsp90
MX2014007878A (es) Formulaciones de (+) - 2 - [1 - (3 - etoxi - 4 - metoxi - fenil) - 2 - metansulfonil - etil] - 4 - acetil aminoisoindolin - 1, 3 - diona.
PE20170914A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
AR084144A1 (es) Compuestos y metodos para restaurar la piel
PE20142337A1 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
MX2021009909A (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
UY31824A (es) Nuevos compuestos